The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera (PV).

Data from a 2-part single-institution, open-label, dose-escalation phase I study showed a 75% overall response rate when idasanutlin was given as a monotherapy or in combination with pegylated interferon, said John Mascarenhas, MD, at the 2017 ASH Annual Meeting.  Click the link below for the full story:

Nutlin Antagonist Shows Activity in Polycythemia Vera

The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera.  

Targeted Oncology